Edition:
United Kingdom

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

9.43USD
14 Jun 2019
Change (% chg)

-- (--)
Prev Close
$9.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
417,166
52-wk High
$15.47
52-wk Low
$6.00

Latest Key Developments (Source: Significant Developments)

Dermira Qtrly Loss Per Share $1.49
Tuesday, 7 May 2019 

May 7 (Reuters) - Dermira Inc ::DERMIRA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 REVENUE $2.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $2.5 MILLION.QTRLY LOSS PER SHARE $1.49.  Full Article

Dermira Announces Proposed Public Offering Of Common Stock
Monday, 18 Mar 2019 

March 18 (Reuters) - Dermira Inc ::DERMIRA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.DERMIRA INC - INTENDS TO OFFER $110.0 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.DERMIRA INC - ALL OF SHARES WILL BE OFFERED AND SOLD BY DERMIRA.  Full Article

Dermira Inc Says All Three Doses Of Lebrikizumab Met Primary Endpoint With Statistical Significance
Monday, 18 Mar 2019 

March 18 (Reuters) - Dermira Inc ::DERMIRA ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2B STUDY OF LEBRIKIZUMAB IN PATIENTS WITH ATOPIC DERMATITIS.DERMIRA INC - ALL THREE DOSES OF LEBRIKIZUMAB MET PRIMARY ENDPOINT WITH STATISTICAL SIGNIFICANCE.DERMIRA INC - LEBRIKIZUMAB WAS WELL-TOLERATED; SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES.DERMIRA INC - LEBRIKIZUMAB WAS WELL-TOLERATED; SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES.DERMIRA INC - EFFICACY AND SAFETY PROFILE SUPPORT ADVANCEMENT INTO PHASE 3; PLANNED BY END OF 2019.  Full Article

Dermira Inc Entered Into First Amendment To License Agreement With Roche
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Dermira Inc ::DERMIRA INC - ENTERED INTO FIRST AMENDMENT TO LICENSE AGREEMENT WITH ROCHE.DERMIRA INC - AMENDMENT AMENDS LICENSE AGREEMENT, DATED AUGUST 8, 2017, BY AND BETWEEN DERMIRA AND ROCHE.DERMIRA INC - AMENDMENT PROVIDES ROCHE WILL SUPPLY DERMIRA WITH UP TO APPROXIMATELY $16 MILLION IN EXISTING LEBRIKIZUMAB DRUG SUBSTANCE, FREE OF CHARGE.DERMIRA- AMENDMENT CUTS CO'S MILESTONE PAYMENT OBLIGATION TO ROCHE IN CONNECTION WITH INITIATION OF PHASE 3 CLINICAL STUDY OF LEBRIKIZUMAB TO $20 MILLION.DERMIRA INC - AMENDMENT REVISES CO'S OBLIGATION TO MAKE ROYALTY PAYMENTS REPRESENTING PERCENTAGES OF TIERS OF ANNUAL NET SALES OF LEBRIKIZUMAB.DERMIRA INC - UNDER AMENDMENT, PERCENTAGES OF TIERS OF ANNUAL NET SALES OF LEBRIKIZUMAB ARE RAISED.DERMIRA - AMENDMENT ELIMINATES CO'S MILESTONE PAYMENT OBLIGATION TO ROCHE UPON SUBMISSION OF FIRST APPLICATION FOR APPROVAL OF LEBRIKIZUMAB IN U.S..  Full Article

Dermira Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Dermira Inc ::DERMIRA INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING.  Full Article

Dermira Reports Q3 Loss Per Share $1.58
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Dermira Inc ::DERMIRA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.58.Q3 EARNINGS PER SHARE VIEW $-1.63 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $700,000.Q3 REVENUE VIEW $450,000 -- THOMSON REUTERS I/B/E/S.MANAGEMENT REITERATES ITS PREVIOUSLY ISSUED FINANCIAL GUIDANCE FOR FULL YEAR 2018.  Full Article

Dermira Qtrly Loss Per Share $‍1.34​
Thursday, 22 Feb 2018 

Feb 22 (Reuters) - Dermira Inc ::DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.DERMIRA INC - ‍OLUMACOSTAT GLASARETIL TOPLINE PHASE 3 DATA EXPECTED Q1 2018​.DERMIRA INC QTRLY LOSS PER SHARE $‍1.34​.DERMIRA INC QTRLY ‍COLLABORATION AND LICENSE REVENUE $1.3 MILLION VERSUS $22.5 MILLION​.  Full Article

Dermira Initiates Mid-Stage Study Testing Eczema Treatment
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - Dermira Inc ::DERMIRA INITIATES PHASE 2B DOSE-RANGING STUDY EVALUATING LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.DERMIRA INC - ‍TOPLINE RESULTS FROM PHASE 2B DOSE-RANGING STUDY​ EXPECTED IN FIRST HALF OF 2019.  Full Article

Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Dermira Inc :Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis.Dermira Inc - ‍FDA decision on new drug application for glycopyrronium tosylate expected by June 30, 2018​.Dermira Inc - qtrly net loss per share, basic and diluted $4.30 ‍​.Dermira Inc - updating its financial guidance for full year 2017; now expects collaboration and license revenue of approximately $4.3 million for FY​.  Full Article

Dermira and UCB agree to end collaboration agreement for Cimzia
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Dermira Inc :Dermira and UCB agree to end collaboration agreement for Cimzia.Dermira Inc - ‍Dermira to transition development and commercialization responsibility for Cimzia (Certolizumab Pegol) in psoriasis back to UCB​.Dermira Inc - ‍collaboration agreement will terminate on February 15, 2018 and companies anticipate completion of transition by such date​.Dermira Inc - ‍pursuant to collaboration agreement, there are no termination or penalty payments required by either party​.Dermira - for repurchase of all product rights, licenses and intellectual property relating to cimzia, ucb will pay to dermira $11.0 million by Nov 13.  Full Article

BRIEF-Dermira Inc Entered Into First Amendment To License Agreement With Roche

* DERMIRA INC - ENTERED INTO FIRST AMENDMENT TO LICENSE AGREEMENT WITH ROCHE